Medivir Rises on Plans for Hepatitis C Study: Stockholm Mover

Medivir AB (MVIRB), a Swedish biotech company, rose the most in eight months after announcing a mid-stage study for a hepatitis C treatment combining simeprevir with VX-135, developed by Vertex Pharmaceuticals Inc. (VRTX)

The shares rose as much as 12 percent, the biggest intraday gain since February, and were up 11 percent at 67.25 kronor as of 3:11 p.m.

The proof-of-concept study will start early next year to investigate tolerability, safety and viral cure rates after a 12-week period, Stockholm-based Medivir said today in a statement. Simeprevir, developed by Johnson & Johnson with Medivir, is a hepatitis C treatment now in late-stage studies and is also known as TMC435. VX-135 is designed to attack the hepatitis C virus in a different way, Medivir said.

“This study will broaden our understanding of simeprevir, which we believe has the necessary characteristics to become a key component of future hepatitis C treatment regimens,” Charlotte Edenius, who heads Medivir’s research and development department, said in the statement.

Johnson & Johnson and Vertex will share the costs for the study equally and there are no up-front or milestone payments connected to the agreement.

To contact the reporter on this story: Janina Pfalzer in Stockholm at

To contact the editor responsible for this story: Christian Wienberg at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.